Effects of eicosapentaenoic acid on platelet activation markers and cell adhesion molecules in hyperlipidemic patients with Type 2 diabetes mellitus

J Diabetes Complications. May-Jun 2003;17(3):153-9. doi: 10.1016/s1056-8727(02)00172-1.

Abstract

We compared the levels of microparticles, platelet activation markers, soluble cell adhesion molecules, soluble selectins, and antioxidized low-density lipoprotein (anti-Ox LDL) antibody between patients with hyperlipidemia and control subjects. Binding of anti-glycoprotein (GP) IIb/IIIa and anti-GPIb monoclonal antibodies to platelets did not differ significantly between the hyperlipidemic patients and controls. However, expression of activation markers (CD62P, CD63, PAC-1, and annexin V) by platelets was higher in the hyperlipidemic patients with Type 2 diabetes. The levels of platelet-derived microparticles (PDMPs) and monocyte-derived microparticles (MDMPs) were significantly different in hyperlipidemic patients with Type 2 diabetes and controls. Soluble P-selectin (sP-selectin), soluble E-selectin (sE-selectin), and anti-Ox LDL antibody also showed higher levels in the hyperlipidemic patients with Type 2 diabetes. After treatment with eicosapentaenoic acid (EPA), the levels of CD62P, CD63, annexin V, PDMPs, and MDMPs, sE-selectin, and oxidized LDL antibody were reduced significantly. Triglyceride (TG) and total cholesterol levels were also decreased. Anti-Ox LDL antibodies and MDMPs were correlated positively with platelet CD62P (plt-CD62P) levels. These findings suggest that in hyperlipidemic patients with Type 2 diabetes, EPA may prevent complications caused by oxidized LDL, E-selectin, and activated platelets or monocytes.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / blood
  • Autoantibodies / blood
  • Cell Adhesion Molecules / blood*
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / immunology
  • Eicosapentaenoic Acid / pharmacology*
  • Female
  • Humans
  • Hyperlipidemias / blood*
  • Hyperlipidemias / complications
  • Hyperlipidemias / immunology
  • Leukocyte Count
  • Male
  • Middle Aged
  • Platelet Activation / drug effects
  • Platelet Activation / physiology*
  • Platelet Count
  • Platelet Glycoprotein GPIIb-IIIa Complex / analysis
  • Reference Values
  • Triglycerides / blood

Substances

  • Antigens, CD
  • Autoantibodies
  • Cell Adhesion Molecules
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Triglycerides
  • Eicosapentaenoic Acid